SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally is drawing attention to Starknets quantum-resistant STARK technology and speculation about a possible transition from an Ethereum L2 to an independent L1. Traders are largely bullish and chasing momentum, while others warn the move could fade and point to profit-taking.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

A reported Hyperbridge exploit involving an Ethereum-based wrapped DOT token is fueling security concerns, though some traders emphasize that native Polkadot DOT was not affected. The discussion also reflects sharp disagreement over DOTs weak price performance and whether recent rebounds can hold.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

AEROs rally has traders focused on the planned AerodromeVelodrome merger and expansion into a unified multichain liquidity protocol, which the community sees as a potential growth catalyst. Sentiment is largely bullish, though some traders question whether the rollout is already priced in and point to pullback and token-emission risks.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa and the pending FDA review decision are driving discussion, with traders debating the potential for priority review against regulatory risk. The community is also weighing the muted share-price response and managements go-it-alone commercialization strategy against hopes for a partnership or buyout.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas rally toward fresh highs and bullish technical momentum are drawing attention, with traders citing breakout patterns and strong price action. Sentiment is mostly positive, though some see the stock as overextended and expect profit-taking or a pullback.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Traders are focused on reports of FDA review documents showing a weaker response rate for daraxonrasib in KRAS G12D pancreatic cancer than in other mutation subgroups, raising questions about the drugs efficacy across patients and opening a competitive debate with Verastems G12D program. Some investors view the subgroup response data as concerning, while others argue that overall survival and progression-free-survival results matter more and caution that subgroup comparisons may not be definitive.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobes post-earnings reaction is driving discussion: traders note the quarterly beat and raised full-year outlook, but focus on softer-than-expected forward revenue guidance and slowing recurring-revenue growth. The debate centers on whether AI adoption will translate into durable paid growth, with some viewing the selloff as excessive and others worried about AI disruption and the incoming CEOs strategy.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastems planned VS-7375 clinical update across pancreatic, lung and colorectal cancers is the main focus, with traders comparing encouraging GenFleet results and recent questions about competing KRAS drugs against the need for Verastems own data to confirm efficacy, durability and tolerability. Sentiment is hopeful but cautious, and some investors are frustrated that pipeline developments have not lifted the share price more; RAMP 201 ovarian-cancer analyses are a secondary topic.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

PENGUs persistent selloff and underperformance versus broader crypto markets dominate the discussion, with traders debating whether the weakness is a buying opportunity or reflects a lack of fresh catalysts. Some holders remain bullish on the Pudgy Penguins brand and future utility, while skeptics point to repeated failed rebounds and selling pressure.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

AMRN is drawing attention amid a steep selloff and new lows, with holders voicing frustration over the share-price decline and management while debating the companys cash position and prospects. Speculation about a rebound or strategic sale competes with concerns over the pending LR-EtEPA patent, the EMT-2 results and weak reimbursement prospects in China.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tevogen CEO Says ‘Actively Evaluating’ Potential Acquisitions 

Equity

The announcement comes on the heels of the company announcing that it has entered into a letter of intent to evaluate a deal with another pharmaceutical company called Apozel Pharmaceuticals.


Tevogen Bio (NASDAQ:TVGN) Sets New 12-Month Low - Here's What Happened

Tevogen Bio (NASDAQ:TVGN) Reaches New 12-Month Low - Should You Sell...

Tevogen Shares Take Further Beating On Gauging Deal With Apozel Pharmaceuticals

If the deal goes through, it could provide Tevogen with an established generics platform, the company said.

Tevogen Bio (TVGN) to Release Earnings on Wednesday

Tevogen Bio (NASDAQ:TVGN) will be releasing earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Tevogen Bio (NASDAQ:TVGN) Trading 7.9% Higher - Should You Buy?

Tevogen Bio (NASDAQ:TVGN) Stock Price Up 7.9% - Should You Buy...

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's Why

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's What Happened...

Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Time to Sell?

Tevogen Bio (NASDAQ:TVGN) Trading Down 1.8% - Here's What Happened...

Tevogen Bio (NASDAQ:TVGN) Price Target Cut to $5.00 by Analysts at D. Boral Capital

D. Boral Capital decreased their target price on shares of Tevogen Bio from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday...

Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results

Tevogen Bio (NASDAQ:TVGN - Get Free Report) posted its earnings results on Friday. The company reported ($0.03) earnings per share for the quarter...

Buy When There’s Blood in the Streets: Why the DeepSeek Rout May Be Good News for Microsoft Stock

Microsoft’s stock presents a buying opportunity due to its strong financials, strategic partnerships, and potential to benefit from cheaper AI models in the long run.

Tevogen, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ.

Tevogen Inc.

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Tevogen Bio Holdings Inc.

$TVGN  because using algos someone is controlling price in order to get our shares cheaper. This is going to explode in few weeks. Something very strong is brewing. NFA. Best regards.

Nacho GCS

$TVGN OFFICIAL: NASDAQ COMPLIANCE FULLY SECURED! 
 
Fresh 8-K filed! Nasdaq sent official written confirmation (Sept 29) that $TVGN has regained full compliance with the $50M Market Value requirement (Rule 5450(b)(2)(A)). 
 
All compliance matters with Nasdaq are now OFFICIALLY CLOSED. No delisting risk. Float locked, balance sheet clean, reg issues solved. 
 
Next stop: Pending MSO/CRO definitive 8-K. 
 
$TVGN #Biotech #Bullish #Nasdaq

$TVGN Valuation Model based on Revenue Mix (MSO/CRO + Tevogen.AI Licences) 🧬🤖 
 
Today there are only 6,4 million shares (float 3,5M - 4,2M shares). But even Assuming worst case fully diluted ~21M OS  (including CEO 8M sh ONLY if $1B revenue milestones from last SEC filing on 16th sept): 
 
🔹 Base Case ($250M Rev): $180M MSO + $70M AI = ~$65 - $70 / sh 
🔹 Bull Case ($600M Rev): $400M MSO + $200M AI = ~$170 - $180 / sh 
🔹 TechBio Mega Case ($1B Rev): $500M MSO + $500M AI = ~$360 - $380 / sh 
 
AI SaaS multiples (10x-15x) completely dwarf traditional CRO valuation. High margins = massive repricing. 📈 
 
NFA - Do your own DD

Feed

News

Sentiment

Earnings

Fundamentals

Info

TVGN Tevogen Bio Holdings Inc.

Fundamentals

Latest TVGN News